Celltrion Submits Denosumab BLA to FDA: On November 30, 2023, it was reported that Celltrion had completed submission of its application to the FDA for CT-P41, its denosumab biosimilar of Amgen’s PROLIA and XGEVA…. By: Goodwin
Previous Story
A GDPR for AI? Political Agreement Reached on the EU AI Act
Next Story
India’s Digital Personal Data Protection Act 2023 vs. the GDPR: A Comparison
